CARLSBAD, Calif., Sept. 7, 2023 /PRNewswire/ -- Navigate BioPharma Services, Inc., a specialty laboratory offering high-quality, innovative precision medicine solutions and bioanalytics for clinical development and diagnostic applications, announces a strategic collaboration with BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, to explore opportunities to develop and commercialize flow cytometry-based companion diagnostics and tools for clinical decisions..

加利福尼亚州卡尔斯巴德，2023年9月7日/PRNewswire/-导航生物制药服务公司是一家专业实验室，为临床开发和诊断应用提供高质量，创新的精准医学解决方案和生物分析，宣布与BD（Becton，Dickinson and Company）（纽约证券交易所：BDX），一家领先的全球医疗技术公司，探索开发和商业化基于流式细胞仪的伴随诊断和临床决策工具的机会。。

The collaboration aims to leverage the complementary expertise and capabilities of both companies to provide end-to-end solutions for pharmaceutical and biotechnology companies developing novel therapies that require companion diagnostics, tests intended to match patients with life-changing treatments, and critical clinical trial applications that utilize flow cytometry.

该合作旨在利用两家公司互补的专业知识和能力，为制药和生物技术公司提供端到端的解决方案，为开发需要伴随诊断的新疗法，旨在使患者与改变生活的疗法相匹配的测试以及关键的临床试验应用利用流式细胞仪。

Importantly, this collaboration aims to address a critical gap in the clinical trial field for an integrated solution provider from method development to commercialization..

重要的是，这项合作旨在解决从方法开发到商业化的集成解决方案提供商在临床试验领域的关键差距。。

'Flow cytometry-based companion diagnostics can help identify patients who are most likely to benefit from a specific therapy, monitor their response to treatment, and optimize dosing and safety from a patient sample,' said Dr. Shabnam Tangri, Chief Scientific Officer at Navigate BioPharma. 'Advances in flow cytometry technology made by BD can enable in vitro diagnostics (IVD) testing to be executed with accuracy, automation and standardization across all elements of the workflow.'.

“基于流式细胞术的伴随诊断可以帮助识别最有可能从特定治疗中受益的患者，监测他们对治疗的反应，并优化患者样本的剂量和安全性，”Navigate首席科学官Shabnam Tangri博士说生物制药“BD所做的流式细胞术技术的进步可以使体外诊断（IVD）测试能够在工作流程的所有元素中以准确，自动化和标准化的方式执行。

Vipin Bhambhani, VP of Clinical Flow Solutions, BD Biosciences said, 'Flow cytometry is a powerful technique that can enable high-sensitivity, affordable testing with fast turnaround time. The collaboration will combine Navigate BioPharma's extensive experience in designing and validating biomarker assays for clinical trials and regulatory submissions with the broad BD portfolio of flow cytometry instruments, reagents, software, and IVD development services, to potentially accelerate the delivery of innovative personalized therapies to patients who need them most.'.

BD Biosciences临床流动解决方案副总裁Vipin Bhambhani说，“流式细胞仪是一种功能强大的技术，可以实现高灵敏度，经济实惠的测试，并且周转时间快。该合作将结合Navigate BioPharma在设计和验证临床试验和监管提交的生物标志物检测方面的丰富经验，以及广泛的BD流式细胞仪，试剂，软件和IVD开发服务组合，以潜在地加速向患者提供创新的个性化治疗。最需要他们“。

The parties intend to collaborate with biopharma organizations in the following areas:

双方打算在以下领域与生物制药组织合作：

Accelerating the delivery of personalized therapies to patients by using biomarker-based assays as an essential clinical trial or companion diagnostic tool for cancer and other diseases.

通过使用基于生物标志物的分析作为癌症和其他疾病的基本临床试验或伴随诊断工具，加速向患者提供个性化治疗。

Addressing the latest health authority expectations for high-sensitivity minimal residual disease (MRD) monitoring assays as surrogate endpoints.

解决卫生当局对高灵敏度微小残留病（MRD）监测分析作为替代终点的最新期望。

Providing flexible and integrated solutions that can help collaborators achieve their clinical and regulatory goals by leveraging the capabilities of flow cytometry.

提供灵活而集成的解决方案，通过利用流式细胞仪的功能，帮助合作者实现其临床和监管目标。

Expanding the range of therapeutic options and biomarkers that can be analyzed, including complex target and drug combinations, rare cell populations, cell signaling and function.

扩大可分析的治疗选择和生物标志物的范围，包括复杂的靶标和药物组合，稀有细胞群，细胞信号传导和功能。

Increasing the effectiveness of biomarker profiling and enhancing the quality and efficiency of the companion diagnostic development process by utilizing the cutting-edge technologies and services offered by both companies, and Navigate BioPharma's expertise in developing specialty high-complexity and high-dimension flow cytometry and execution through regulated clinical trial testing..

通过利用两家公司提供的尖端技术和服务，提高生物标志物分析的有效性，提高伴随诊断开发过程的质量和效率，并导航生物制药在开发专业高复杂度和高维流式细胞仪方面的专业知识，并通过规范的临床试验测试。。

Navigate BioPharma Services, Inc., an independently operating subsidiary within the Novartis group of companies, is a leading provider of innovative biomarker and specialty bioanalytic solutions for clinical development and companion diagnostic applications. Over the past decade, Navigate BioPharma has built and developed its exclusive library of assays, methodologies, and biomarker solutions.  Their extensive expertise offers unique, accurate, reliable, and cost-effective solutions for its customers and partners.

Navigate BioPharma Services，Inc.是诺华集团公司的独立运营子公司，是临床开发和伴随诊断应用的创新生物标志物和专业生物分析解决方案的领先供应商。在过去的十年中，Navigate BioPharma建立并开发了其独家的分析，方法和生物标记解决方案库。他们广泛的专业知识为客户和合作伙伴提供独特，准确，可靠和具有成本效益的解决方案。

For more information about Navigate BioPharma's services, please visit www.navigatebp.com or connect with them on LinkedIn at www.linkedin.com/company/navigatebp/..

有关Navigate BioPharma服务的更多信息，请访问www.navigatebp.com或在LinkedIn上与它们连接，网址为www.LinkedIn.com/company/navigatebp/。。

Media and Customer Contact information: To incorporate this new assay or any other proprietary Navigate technology in an upcoming clinical trial study contact: Nick Sanna, Head of Business Development & Strategic Alliances, Navigate BioPharma Services, Inc. Phone: (760) 602-1409. Email: [email protected]..

媒体和客户联系信息：将此新测定或任何其他专有导航技术纳入即将进行的临床试验研究联系人：Navigate BioPharma Services，Inc。业务发展与战略联盟负责人Nick Sanna电话：（760）602-1409。电子邮件：[电子邮件保护]。。

SOURCE Navigate BioPharma Services, Inc.

源导航生物制药服务公司。